Tectonic Therapeutic Inc
TECX21.070USD
+0.340+1.64%
交易中 （美東）報價延遲15分鐘
393.41M總市值
虧損本益比TTM
關於 Tectonic Therapeutic Inc 公司
Tectonic Therapeutic, Inc. 是一家生物技術公司。該公司專注於發現和開發調節 G 蛋白偶聯受體 (GPCR) 活性的治療性蛋白質和抗體。利用其名爲 GEODe（專爲最佳發現而設計的 GPCR）的技術平臺，該公司專注於開發生物藥物，以克服 GPCR 靶向藥物發現的現有挑戰並利用人體來改變疾病進程。該公司的領先項目 TX000045 (TX45) 是一種 Fc-鬆弛素融合分子，可激活 RXFP1 受體，即激素鬆弛素的 GPCR 靶點。TX45 正在 Ia/Ib 期臨牀試驗中進行評估，作爲治療 2 組肺動脈高壓伴射血分數保留的心力衰竭 (HFpEF) 的潛在方法。其第二個項目針對遺傳性出血性毛細血管擴張症 (HHT)。
公司簡介
公司代碼TECX
公司名稱Tectonic Therapeutic Inc
上市日期Jun 21, 2018
CEODr. Alise S. Reicin, M.D.
員工數量51
證券類型Ordinary Share
年結日Jun 21
公司地址490 Arsenal Way
城市WATERTOWN
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02472
電話13396663320
網址https://tectonictx.com/
公司代碼TECX
上市日期Jun 21, 2018
CEODr. Alise S. Reicin, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.25K
-0.30%
Dr. Peter Mcnamara, Ph.D.
Dr. Peter Mcnamara, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.53K
+344.82%
Dr. Praveen P. Tipirneni, M.D.
Dr. Praveen P. Tipirneni, M.D.
Independent Director
Independent Director
3.04K
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Daniel Lochner
Mr. Daniel Lochner
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Terrance G. (Terry) Mcguire
Mr. Terrance G. (Terry) Mcguire
Independent Director
Independent Director
--
--
Dr. Marc Schwabish, Ph.D.
Dr. Marc Schwabish, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Phillip B. (Phil) Donenberg
Mr. Phillip B. (Phil) Donenberg
Independent Director
Independent Director
--
--
Mr. Stefan Vitorovic
Mr. Stefan Vitorovic
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.25K
-0.30%
Dr. Peter Mcnamara, Ph.D.
Dr. Peter Mcnamara, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.53K
+344.82%
Dr. Praveen P. Tipirneni, M.D.
Dr. Praveen P. Tipirneni, M.D.
Independent Director
Independent Director
3.04K
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Daniel Lochner
Mr. Daniel Lochner
Chief Financial Officer
Chief Financial Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月22日 週二
更新時間: 7月22日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Springer Timothy A
23.68%
Fidelity Management & Research Company LLC
14.99%
Deep Track Capital LP
7.51%
TAS Partners, L.L.C.
7.41%
EcoR1 Capital, LLC
5.01%
Other
41.40%
持股股東
持股股東
佔比
Springer Timothy A
23.68%
Fidelity Management & Research Company LLC
14.99%
Deep Track Capital LP
7.51%
TAS Partners, L.L.C.
7.41%
EcoR1 Capital, LLC
5.01%
Other
41.40%
股東類型
持股股東
佔比
Individual Investor
27.37%
Hedge Fund
24.98%
Investment Advisor
22.57%
Corporation
10.93%
Investment Advisor/Hedge Fund
7.56%
Venture Capital
2.74%
Research Firm
2.25%
Pension Fund
0.12%
Family Office
0.05%
Other
1.43%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
178
18.44M
98.77%
+1.52M
2025Q1
184
18.15M
106.94%
+1.93M
2024Q4
153
13.88M
94.13%
+369.61K
2024Q3
148
13.13M
89.69%
+166.42K
2024Q2
151
11.92M
81.47%
+8.19M
2024Q1
179
2.57M
67.87%
-1.12M
2023Q4
200
2.14M
56.67%
-1.83M
2023Q3
236
2.28M
60.58%
-1.25M
2023Q2
243
1.76M
47.84%
-1.94M
2023Q1
262
2.00M
54.58%
-1.52M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Springer Timothy A
4.42M
23.68%
+196.29K
+4.64%
Apr 11, 2025
Fidelity Management & Research Company LLC
2.80M
14.99%
+1.28M
+84.63%
Mar 31, 2025
Deep Track Capital LP
1.40M
7.51%
--
--
Mar 31, 2025
TAS Partners, L.L.C.
1.38M
7.41%
+412.50K
+42.52%
Apr 03, 2025
EcoR1 Capital, LLC
935.12K
5.01%
+85.98K
+10.13%
Mar 31, 2025
Farallon Capital Management, L.L.C.
853.05K
4.57%
+140.00K
+19.63%
Mar 31, 2025
Polaris Partners
657.98K
3.52%
-500.00K
-43.18%
Apr 03, 2025
5AM Ventures
511.66K
2.74%
-85.00K
-14.25%
Mar 31, 2025
Prosight Capital
398.88K
2.14%
+398.88K
--
Mar 31, 2025
The Vanguard Group, Inc.
361.17K
1.93%
+120.00
+0.03%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.02%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.8%
iShares Micro-Cap ETF
佔比0.05%
Invesco Nasdaq Biotechnology ETF
佔比0.04%
ProShares Ultra Nasdaq Biotechnology
佔比0.04%
iShares Biotechnology ETF
佔比0.02%
Global X Russell 2000 ETF
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
公告日期
類型
比率
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
